Amicus Therapeutics (FOLD) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amicus Therapeutics Announces Full-Year 2014 Financial Results and Corporate Updates
March 3, 2015 4:01 PM ESTMAA Submission for Migalastat Monotherapy for Fabry Disease on Track for Mid-2015 FDA Meeting Scheduled in 1Q15 to Discuss U.S. Pathway
Next-Generation Pompe ERT Set to Enter Clinic in 2H15
CRANBURY, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the full-year ended December 31, 2014. The Company also provided program updates and reiterated full-year 2015 net cash spend... More
